Cellular senescence promotes macrophage-to-myofibroblast transition in chronic ischemic renal disease
Cellular senescence participates in the pathophysiology of post-stenotic kidney damage, but how it regulates tissue remodeling is incompletely understood. Macrophage-myofibroblast transition (MMT) contributes to the development of tissue fibrosis. We hypothesized that cellular senescence contributes to MMT and renal fibrosis in mice with renal artery stenosis (RAS). INK-ATTAC mice expressing p16<sup>INK-4a</sup> and green fluorescent protein in senescent cells were assigned to control or unilateral RAS, untreated or treated with AP20187 (an apoptosis inducer in p16<sup>INK-4a</sup>-expressing cells) for 4 weeks. Renal perfusion was studied in vivo using micro-MRI, and kidney morphology, senescence, and MMT ex vivo. Cellular senescence was induced in human renal proximal tubular epithelial cells (HRPTEpiC) in vitro, and interferon-induced transmembrane protein-3 (IFITM3), a cellular senescence vector, was silenced (siRNA) or over-expressed (plasmid). HRPTEpiC were then co-incubated with macrophages with silenced integrin-3 (ITGB3), a regulator of mesenchymal transitions. CD68/p16<sup>INK-4a</sup>/α-SMA co-expression and senescence markers were studied. Murine RAS kidneys showed increased expression of p16<sup>INK-4a</sup> and MMT markers (F4/80, α-SMA) vs. controls, which decreased after AP20187, as did renal fibrosis and plasma creatinine, whereas renal perfusion increased. IFITM3 and ITGB3 expression were upregulated in senescent HRPTEpiC or co-cultured macrophages, respectively. MMT markers and TGF-β/Smad3 expression also rose in these macrophages and decreased after IFITM3 or ITGB3 silencing. p16<sup>INK-4a</sup>-expressing macrophages may regulate interstitial fibrosis in RAS via MMT. This process is associated with elevated expression of ITGB3 and TGF-β/Smad3 pathway activation through neighboring senescent cell-derived IFITM3. These findings may implicate MMT as a therapeutic target in ischemic kidneys.
Authors
- James L. Kirkland (ORCID: https://orcid.org/0000-0003-1676-4905)
- Kyra L. Jordan
- Fei Yuan (ORCID: https://orcid.org/0000-0002-9681-6367)
- Lilach O. Lerman (ORCID: https://orcid.org/0000-0002-3271-3887)
- Amir Lerman (ORCID: https://orcid.org/0000-0002-9446-5313)
- Wenqi Ma (ORCID: https://orcid.org/0000-0002-0287-8496)
- Tamar Tchkonia (ORCID: https://orcid.org/0000-0003-4623-7145)
- Xiangyang Zhu (ORCID: https://orcid.org/0000-0001-7146-0459)
- Seo Rin Kim (ORCID: https://orcid.org/0000-0003-3552-0519)
- Yu Zhao (ORCID: https://orcid.org/0000-0001-9025-2014)
- Yiqiang Zhang (ORCID: https://orcid.org/0000-0003-0691-6645)
- Hui Tang (ORCID: https://orcid.org/0000-0002-8060-4896)
Institutions
- Mayo Clinic (US)
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- WinnMed (US)
- Shanghai Children's Medical Center (CN)
- Zhongda Hospital Southeast University (CN)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Cell Death and Disease
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1038/s41419-025-07666-1
- Citations
- 9
- Primary Topic
- Renal and Vascular Pathologies
- Type
- article
- Field-Weighted Citation Impact
- 13.67
Funders
- National Institute on Aging
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases